首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 以基因为基之药物开发

表观遗传学市场规模、份额和成长分析（按产品、技术、方法、应用、最终用途和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1898713

表观遗传学市场规模、份额和成长分析（按产品、技术、方法、应用、最终用途和地区划分）—产业预测（2026-2033 年）

Epigenetics Market Size, Share, and Growth Analysis, By Product (Kits & Reagents, Instruments), By Technology (DNA Methylation, Histone Methylation), By Technique, By Application, By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，表观遗传学市场规模将达到 18.4 亿美元，到 2025 年将达到 21.1 亿美元，到 2033 年将达到 63.6 亿美元，在预测期（2026-2033 年）内，复合年增长率为 14.8%。

由于表观遗传学在增进我们对基因调控的理解（超越传统DNA定序）、增强疾病监测以及促进个人化医疗方面发挥关键作用，因此该市场正经历着显着增长。预计投资的增加将进一步推动该行业的扩张。然而，全球癌症发生率的上升仍然是一个不容忽视的挑战，每年导致数百万新增病例和死亡。表观遗传疾病的治疗利用多种标靶酵素的抑制剂，例如HDM、HMT、DNMT、HAT和HDAC，而免疫疗法和化疗等传统治疗方法则作为补充手段。表观遗传疗法在治疗癌症和神经系统疾病方面展现出巨大的潜力。在人们对癌症日益关注的背景下，这些因素共同推动了表观遗传学市场的强劲成长。

表观遗传学市场驱动因素

表观遗传学市场的发展主要受多种慢性疾病（包括癌症和心血管疾病）发生率上升的驱动。 DNA甲基化和组蛋白修饰等表观遗传改变在这些疾病的进展和发展中起着关键作用。随着精准医疗的日益普及，大量资金和研究投入正涌入表观遗传疗法的研发，展现出个人化治疗的巨大潜力。这一趋势不仅凸显了表观遗传学在现代医疗保健中的重要作用，也推动了相关产品和服务的需求，为该领域的蓬勃发展创造了良好的环境。

表观遗传学市场限制因素

エピジェネティクス市场は、研究开発および治疗开発に伴う多额の费用により、重大な课题に直面しています。この分野は次世代定序やクロマチン免疫沉淀分析法といった高度な技术に大きく依存しており、これらは高い导入コストと运用コストを伴います。こうした财政的障壁は、特にヘルスケア予算が限られている発展途上地域において、必须のエピジェネティックツールや治疗方法へのアクセスを制限しています。その结果、多くの机関や研究者がエピジェネティクスの进歩を十分に探求するために必要な资源に投资できないため、市场の成长可能性が阻害されています。この财政的制约は、エピジェネティックソリューションの全体的な発展とアクセシビリティに大きく影响しています。

表观遗传学市场趋势

表观遗传学市场呈现显着的发展趋势，这主要得益于表观遗传编辑技术的进步。这些创新技术，包括基于 CRISPR/Cas9 的工具，使研究人员能够精确地修饰表观遗传标记，从而在不改变 DNA 序列本身的情况下，对基因调控进行精细的研究。这种精准性为包括癌症、神经系统疾病和自体免疫疾病在内的多个医学领域开发标靶治疗创造了变革性的机会。随着这些前沿工具的加速应用，表观遗传学研究的模式有望发生巨大变化，从而推动新疗法的开发，并加深我们对复杂生物过程的理解。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Thermo Fisher Scientific Inc.（United States）
Illumina, Inc.（United States）
Merck KGaA（Germany）
QIAGEN NV（Netherlands）
Pacific Biosciences of California, Inc.（United States）
Bio-Rad Laboratories, Inc.（United States）
PerkinElmer, Inc.（United States）
10x Genomics, Inc.（United States）
Active Motif, Inc.（United States）
Zymo Research Corporation（United States）
New England Biolabs, Inc.（United States）
Promega Corporation（United States）
Novartis AG（Switzerland）
Element Biosciences, Inc.（United States）
Dovetail Genomics LLC（United States）
Storm Therapeutics（United Kingdom）

结论与建议

简介目录

Product Code: SQMIG35H2201

Epigenetics Market size was valued at USD 1.84 Billion in 2024 and is poised to grow from USD 2.11 Billion in 2025 to USD 6.36 Billion by 2033, growing at a CAGR of 14.8% during the forecast period (2026-2033).

The epigenetics market is witnessing significant growth due to its critical role in advancing gene regulation knowledge beyond traditional DNA sequencing, enhancing disease research, and facilitating personalized medicine. Increased investments are anticipated to further propel industry expansion. However, the escalating global cancer prevalence presents a notable challenge, with millions of new cases and fatalities reported annually. Various inhibitors targeting enzymes such as HDM, HMT, DNMT, HAT, and HDAC are being utilized for epigenetic disorders, while traditional treatments like immunotherapy and chemotherapy complement these approaches. The potential of epigenetic therapy is promising, particularly in addressing cancer and neurological diseases. Collectively, these factors indicate a robust growth trajectory for the epigenetics market amidst rising cancer concerns.

Top-down and bottom-up approaches were used to estimate and validate the size of the Epigenetics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Epigenetics Market Segments Analysis

Global Epigenetics Market is segmented by Product, Technology, Technique, Application, End-use and region. Based on Product, the market is segmented into Kits & Reagents, Instruments, Enzymes and Services. Based on Technology, the market is segmented into DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification and Chromatin structures. Based on Technique, the market is segmented into NGS, PCR & QPCR, Mass Spectrometry, Sonication and Other Techniques. Based on Application, the market is segmented into Oncology and Non-oncology oncology. Based on End-use, the market is segmented into Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Other Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Epigenetics Market

The epigenetics market is significantly propelled by the increasing incidence of cancer and various chronic diseases, including cardiovascular conditions. Epigenetic changes, including DNA methylation and histone modifications, are crucial in the progression and development associated with these diseases. As the focus on precision medicine continues to grow, substantial financial and research investments are directed toward developing epigenetic therapies, showcasing their potential for personalized treatment options. This trend not only highlights the critical role of epigenetics in modern healthcare but also boosts the demand for related products and services, creating a thriving landscape for advancements in this field.

Restraints in the Epigenetics Market

The epigenetics market faces significant challenges due to the substantial expenses associated with research and therapeutic development. The field relies heavily on advanced technologies such as next-generation sequencing and chromatin immunoprecipitation, which come with high acquisition and operational costs. These financial barriers restrict access to essential epigenetic tools and therapies, particularly in developing regions where healthcare budgets are limited. As a result, the growth potential of the market is hindered, as many institutions and researchers are unable to invest in the necessary resources to explore epigenetic advancements fully. This financial constraint greatly influences the overall development and accessibility of epigenetic solutions.

Market Trends of the Epigenetics Market

The epigenetics market is experiencing a notable trend driven by advancements in epigenetic editing technologies. These innovations, including CRISPR/Cas9-based tools, empower researchers to precisely modify epigenetic marks, facilitating the nuanced study of gene regulation without changing the DNA sequence itself. This precision opens up transformative opportunities for developing targeted therapies across various medical domains, including cancer, neurological diseases, and autoimmune disorders. As adoption of these cutting-edge tools accelerates, the landscape of epigenetic research is set to evolve dramatically, paving the way for new treatment modalities and enhancing our understanding of complex biological processes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Epigenetics Market Size by Product & CAGR (2026-2033)

Market Overview
Kits & Reagents
- Antibodies
- ChIP sequencing kit
- Whole Genomic Amplification kit
- Bisulfite Conversion kit
- RNA sequencing kit
- 5-HMC & 5-MC Analysis Kits& Reagents
- Histones
- Others
Instruments
Enzymes
- Dna-Modifying Enzymes
- Protein-Modifying Enzymes
- Other Enzymes
Services

Global Epigenetics Market Size by Technology & CAGR (2026-2033)

Market Overview
DNA Methylation
Histone Methylation
Histone Acetylation
Large non-coding RNA
MicroRNA modification
Chromatin structures

Global Epigenetics Market Size by Technique & CAGR (2026-2033)

Market Overview
NGS
PCR & QPCR
Mass Spectrometry
Sonication
Other Techniques

Global Epigenetics Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
- Solid tumors
- Liquid tumors
Non-oncology oncology
- Inflammatory diseases
- Metabolic diseases
- Infectious diseases
- Cardiovascular diseases
- Others

Global Epigenetics Market Size by End-use & CAGR (2026-2033)

Market Overview
Academic Research
Clinical Research
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other Users

Global Epigenetics Market Size & CAGR (2026-2033)

North America (Product, Technology, Technique, Application, End-use)
- US
- Canada
Europe (Product, Technology, Technique, Application, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Technology, Technique, Application, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Technology, Technique, Application, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Technology, Technique, Application, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific Biosciences of California, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
10x Genomics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Active Motif, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymo Research Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Element Biosciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dovetail Genomics LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Storm Therapeutics (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments